Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease
Shah N, Bhoopatiraju S, Abraham A, Anderson E, Andreansky M, Bhatia M, Chaudhury S, Cuvelier G, Godder K, Grimley M, Hale G, Kamani N, Jacobsohn D, Ngwube A, Skiles J, Yu L, Shenoy S. Granulocyte Colony-Stimulating Factor Is Safe and Well Tolerated Following Allogeneic Transplantation in Patients with Sickle Cell Disease. Blood 2020, 136: 33. DOI: 10.1182/blood-2020-142696.Peer-Reviewed Original ResearchHematopoietic cell transplantationSickle cell diseaseAbsolute neutrophil countVaso-occlusive episodesG-CSF administrationNeutrophil recoveryG-CSFSCD patientsCell diseaseDay 100Unrelated donor hematopoietic cell transplantationDonor hematopoietic cell transplantationVaso-occlusive pain crisesHemoglobin S levelPrimary graft rejectionShort-course methotrexateAcute chest syndromeLife-threatening complicationsG-CSF useGranulocyte-colony stimulating factorGranulocyte colony-stimulating factorTranscranial Doppler velocitiesDifferent donor sourcesColony-stimulating factorSafety/toxicity